stoxline Quote Chart Rank Option Currency Glossary
  
Ascendis Pharma A/S (ASND)
124.59  -3.05 (-2.39%)    06-17 16:00
Open: 127.64
High: 128.97
Volume: 254,661
  
Pre. Close: 127.64
Low: 123.2
Market Cap: 7,054(M)
Technical analysis
2024-06-17 5:21:35 PM
Short term     
Mid term     
Targets 6-month :  155.8 1-year :  167.91
Resists First :  133.39 Second :  143.75
Pivot price 132.73
Supports First :  116.62 Second :  97.03
MAs MA(5) :  128.65 MA(20) :  131.29
MA(100) :  141.16 MA(250) :  116.47
MACD MACD :  -1.6 Signal :  -1
%K %D K(14,3) :  12.7 D(3) :  23.8
RSI RSI(14): 36.8
52-week High :  161 Low :  85.08
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ASND ] has closed above bottom band by 2.3%. Bollinger Bands are 1.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 129.16 - 130.07 130.07 - 130.76
Low: 120.89 - 122.09 122.09 - 123.01
Close: 122.93 - 124.55 124.55 - 125.8
Company Description

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Headline News

Mon, 17 Jun 2024
Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Chicago Partners Investment Group LLC - Defense World

Mon, 17 Jun 2024
Wellington Management Group LLP Decreases Stake in Ascendis Pharma A/S (NASDAQ:ASND) - Defense World

Sun, 16 Jun 2024
Perceptive Advisors LLC Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND) - MarketBeat

Thu, 13 Jun 2024
Ascendis Pharma A/S (NASDAQ:ASND) Trading Down 4.4% - MarketBeat

Wed, 12 Jun 2024
Ascendis Pharma Updates Corporate Financial Strategy - TipRanks

Tue, 04 Jun 2024
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 57 (M)
Held by Insiders 5.689e+007 (%)
Held by Institutions 0.7 (%)
Shares Short 3,600 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.5452e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -152.5 %
Return on Assets (ttm) -51.3 %
Return on Equity (ttm) -25.6 %
Qtrly Rev. Growth 3.2902e+008 %
Gross Profit (p.s.) 314.4
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -9.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -422 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 743.4
Price to Book value 0
Price to Sales 0
Price to Cash Flow -17.72
Stock Dividends
Dividend 0
Forward Dividend 3.46e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android